Dear Members:
A reminder regarding BEBAS community webinar on August 23, 2023. I am happy to invite you for August 2023 Bioequivalence Bioavailability Sciences Community Webinar on August 23, 2023 @ 11.00 am (US EDT), please mark your calendars appropriately for your time zones and benefit by attending to this webinar.
Formulation and BE/BA Perspectives of Long-Acting Injectables (LAI)
Tathagata Dutta, PhD., CSO JODAS EXPOIM Pvt Ltd.,
Hyderabad, India
Long-Acting Injections (LAI) provide controlled release of the drugs for an extended period of time which might be few days to few months, when administered via intramuscular, subcutaneous, epidural, and intra articular routes. Long-Acting Injections are usually formulated as suspension for injection, microspheres for injection and in situ gel forming implants. Development of Long-Acting Injections is a highly challenging task, be it formulation, analytical, Bioequivalence or Clinical. There are several controversies associated with the use of Long-Acting Injections as well. This discussion aims to throw some light on some of these areas of Long-Acting Injectable formulations.
Biography of Speaker:
Dr. Tathagata Dutta has earned his B.Pharm., M.Pharm and PhD in Pharmaceutical Sciences from Dr. Hari Singh Gour University, Sagar, India and completed his postdoctoral studies from School of Pharmacy & Diamantina Institute for cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, Australia focusing in development of RNAi therapeutics for effective management of cancer. He is an alumni of IIM Calcutta. He held several leadership positions as Chief Scientific Officer (CSO), Vice President (R&D), Executive Director, and Managing Director & CEO of several reputed Multinational Pharmaceutical Companies across the globe for more than two decades. He has been conferred with several National and International Awards and Honors. He has published several international papers in reputed international journals, several patents and had authored several book chapters. He is the editorial board member of several international journals on drug discovery & delivery research. His research interests include novel drug delivery systems, dendrimers, liposomes, polymer bioconjugates, tissue targeted drug delivery systems, nano drug delivery systems, gene therapy, genetic immunization, depot injections, gene delivery, and development of RNAi therapeutics.
You can join the meeting by using gotomeeting link provided below:
Formulation and BA/BE Perspective of Long Acting Injections (LAI) -BEBAS community August Webinar
Formulation and BA/BE Perspective of Long Acting Injections (LAI) -BEBAS community August Webinar
Aug 23, 2023, 11:00 AM – 12:00 PM (America/New_York)
Please join my meeting from your computer, tablet or smartphone.
https://meet.goto.com/829309293
You can also dial in using your phone.
Access Code: 829-309-293
United States: +1 (571) 317-3122
Join from a video-conferencing room or system.
Meeting ID: 829-309-293
Dial in or type: 67.217.95.2 or inroomlink.goto.com
Or dial directly: [email protected] or 67.217.95.2##829309293
------------------------------
Prasad Tata M. Pharm, Ph.D., FCP
Sr. Director-PK/BE
American Regent, Inc.
Princeton NJ
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------